Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 65 publications
The Concise Guide to PHARMACOLOGY 2025/26: G protein-coupled receptors.
Journal: British journal of pharmacology
Published: December 29, 2025
Linsitinib Decreases Thyrotropin-Induced Thyroid Hormone Synthesis by Inhibiting Crosstalk Between Thyroid-Stimulating Hormone and Insulin-Like Growth Factor 1 Receptors in Human Thyrocytes In Vitro and In Vivo in Mice.
Journal: Thyroid : official journal of the American Thyroid Association
Published: December 24, 2024
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors.
Journal: British journal of pharmacology
Published: December 20, 2023
An Orally Efficacious Thyrotropin Receptor Ligand Inhibits Growth and Metastatic Activity of Thyroid Cancers.
Journal: The Journal of clinical endocrinology and metabolism
Published: October 02, 2023
Proximity ligation assay to study TSH receptor homodimerization and crosstalk with IGF-1 receptors in human thyroid cells.
Journal: Frontiers in endocrinology
Published: July 08, 2022
Opposing Effects of EGF Receptor Signaling on Proliferation and Differentiation Initiated by EGF or TSH/EGF Receptor Transactivation.
Journal: Endocrinology
Published: May 24, 2022
Graves' Autoantibodies Exhibit Different Stimulating Activities in Cultures of Thyrocytes and Orbital Fibroblasts Not Reflected by Clinical Assays.
Journal: Thyroid : official journal of the American Thyroid Association
Published: October 29, 2021
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors.
Journal: British journal of pharmacology
Published: September 16, 2021
TSH stimulation of human thyroglobulin and thyroid peroxidase gene transcription is partially dependent on internalization.
Journal: Cellular signalling
Published: August 29, 2021
Combined Immunosuppressive Therapy for Severe Graves Dermopathy.
Journal: Annals of internal medicine
Published: June 21, 2021
Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease.
Journal: The Journal of clinical endocrinology and metabolism
Published: May 18, 2021
Last Updated: 09/26/2026